For all you soon-to-be minted millionaires, I came across

New Post Public Reply Private Reply Replies (0) Message Board
riskreward007
664
For all you soon-to-be minted millionaires, I came across this article today about investing in US govt. I-bonds (which sound like a great investment that few people know about). The full article is below (for those of you without a wsj subscription).

Happy investing soon!

Cheers,
RR007

P.S. One very important point: financial advisers have no incentive to sell I bonds, which don’t pay commissions or charge expenses and are available exclusively from the U.S. government

Quote:
The Safe, High-Return Trade Hiding in Plain Sight

One retirement consultant calls I bonds ‘the best-kept secret in America.’ Right now they’re yielding over 3.5%, nearly risk free.

By Jason Zweig
Wall Street Journal
May 28, 2021

Speculators in cryptocurrencies and in meme stocks like GameStop Corp. GME -6.65% have been bragging for months about earning “10X” or even “100X”—10-fold or 100-fold profits.
That’s nothing.

Here’s how you can make more than 170X, raising your return 177-fold in a single trade. Move your cash from a bank account, where it’s probably earning about 0.02%, into an inflation-protected U.S. savings bond, which will yield 3.54% annualized. Unlike daredevil stock or crypto trading, buying an “I bond” is almost risk-free and delivers significant tax advantages.

Economists say there’s no such thing as a free lunch, but I bonds offer a guarantee from the U.S. government that you can recover your original capital plus any increases in the official cost of living along the way. The only catch is that this isn’t an all-you-can-eat buffet: The maximum purchase is $10,000 per year per account holder (unless you elect to take your tax refund in the form of an I bond).

Ironically, the less you earn and have to invest, the more powerful a tool I bonds are. Sorry, Mr. Bezos.

In today’s yield-parched world, money-market funds are paying 0.02%, bank savings accounts 0.13%, a three-month Treasury bill 0.15% and even a 30-year Treasury bond only 2.25%. The income on I bonds is so juicy, it’s barely below that of leading high-yield or “junk” bond funds, which are much riskier.

If you’ve never heard any of this before, don’t feel bad. Zvi Bodie, a consultant on retirement issues who formerly taught finance at Boston University, says he regularly speaks to groups of financial advisers. When he asks how many are familiar with I bonds, “less than half the hands go up” in the audience.

“I bonds are the best-kept secret in America,” says Mr. Bodie. With a total of just $46.4 billion outstanding, they amount to less than 0.17% of all U.S. debt held by the public, according to the Treasury Department.

That’s partly because financial advisers have no incentive to sell I bonds, which don’t pay commissions or charge expenses and are available exclusively from the U.S. government (see TreasuryDirect.gov).

If four family members each put $10,000 into I bonds, that’s $40,000 on which a financial adviser can’t assess a management fee. At a typical 1% charge, that’s $400 a year the adviser won’t earn.

“So all the advisers, all the brokerage firms—all the places people go to for investing advice—aren’t going to say a word about I bonds,” says Marvin Vinluan, a 34-year-old software developer who lives near Binghamton, N.Y. He often posts information about the securities on Bogleheads.org, a website devoted to low-cost investing.

Introduced in 1998, I bonds were conceived to provide primarily small savers with a positive long-term return after inflation. Their yield consists of a fixed rate for the 30-year life of the bond and an inflation rate, which adjusts semiannually. The current 3.54% applies to I bonds issued until Nov. 1, 2021 and will reset every six months unless the official government rate of inflation stays constant.

What if interest rates or inflation head lower? Yes, the yield can decline. But, unlike with Treasury inflation-protected securities, or TIPS, the yield on I bonds can never go below zero. So they protect against both inflation and deflation, which is pretty amazing.

Interest on I bonds is exempt from state and local income tax. In confiscatory states like California, Hawaii, Minnesota, New York and Oregon, a household with $400,000 in taxable income would have to earn roughly 4% on a taxable asset to equal today’s after-tax I-bond return if rates don’t change.

For income-tax purposes, you can choose to defer declaring your I-bond interest until maturity or you redeem, whichever comes first. That income may be tax-exempt for lower- and middle-income families that use the bond to pay for college tuition.

I bonds aren’t as liquid as a bank account, money fund or Treasury bill. You can’t cash out until you’ve held for 12 months. If you redeem within the first five years, you’ll forfeit the last three months of interest. But they’re as liquid as other 30-year bonds—and, if you sell after the first five years, your full recovery of principal and your ability to match or outpace inflation are both guaranteed.

If you buy an I bond at today’s 3.54% rate and sell it one year and a day from now, you’ll earn 2.65% after the penalty (assuming the rate doesn’t change). That’s roughly quadruple what you’d get from a one-year certificate of deposit or ultra-short-term bond fund.

How are you protecting your portfolio against inflation?

Two types of people need to keep much of their money safe: those who shun risk, and those who seek it.

Cautious folks want a moderate return at low risk. But speculators in hot stocks, cryptocurrencies and whatever else is hopping also need to safeguard some of their assets—to protect against the big losses that big risks can lead to.

For the risk averse, earning a 170-fold return by moving your money from a bank to I bonds is “like GameStop but safe!” exclaims Mr. Vinluan. You get the thrill of giving your return a big boost, while taking no more risk.

For risk seekers, I bonds insure against the chance that some of your bets will go bad.

For everyone, with the Biden administration proposing trillions of dollars in government spending, I bonds are a way of making sure that at least some of your money keeps pace with inflation.


The Safe, High-Return Trade Hiding in Plain Sight
https://www.wsj.com/articles/i-bonds-the-safe...eatst_pos3

I Bonds vs TIPS
https://www.bogleheads.org/wiki/I_Bonds_vs_TIPS

Univec Conglomerate Inc (UNVC) Stock Research Links

UNVC Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 280

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 84

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Clarins Dazzles Austin with Skin Longevity Event

Updated Category News Views 21

Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 299

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 175

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 241

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 176

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 98

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading

Top 5 Most Recently Viewed Articles

Morgan Stanley Projects Strong Upswing for Consumer Finance

Updated Category News Views 259

Morgan Stanley's Positive Outlook for Consumer Finance Stocks Morgan Stanley has recently made an uplifting adjustment to its outlook on consumer finance stocks, now branding them as "attractive." This decision stems from robust fundamentals and an improved regulatory environment, setting an optimistic tone for the sector. Key Drivers of Change The primary catalysts...

Continue Reading
Significant Board Restructuring at O2Gold Inc. Announced

Updated Category News Views 71

O2Gold Board Announces Key Changes O2Gold Inc. (NEX: OTGO.H), a dedicated mineral exploration company, has recently undergone a significant change in its board structure. The company has announced that Roger Lemaitre has resigned from his position as a director. This decision marks a pivotal moment for O2Gold as it continues to navigate its exploration initiatives....

Continue Reading
Taylor Morrison Launches Holiday Initiative to Support Homeowners

Updated Category News Views 265

Help for Homeowners During the Holidays In a time when financial strain can be prominent, especially during the holidays, Taylor Morrison (NYSE: TMHC) is stepping up to lend a hand. The renowned homebuilder has introduced an initiative designed to support homeowners facing the threat of foreclosure. With the holiday season often heightening financial challenges, the...

Continue Reading
flatexDEGIRO Moves Ahead After Ending BaFin Oversight

Updated Category News Views 188

flatexDEGIRO Ends Special Commissioner Mandate FRANKFURT - flatexDEGIRO AG, a prominent German financial services provider, has officially announced the conclusion of the special commissioner mandate set by the Federal Financial Supervisory Authority (BaFin). This change will take effect on a specified date in the future. The company has made significant strides in...

Continue Reading
Investigating Alvotech's Regulatory Challenges After Stock Drop

Updated Category News Views 125

Alvotech Faces Scrutiny over Manufacturing Issues National shareholder rights firm Hagens Berman is currently analyzing Alvotech (NASDAQ: ALVO) regarding potential misrepresentations in their disclosures tied to manufacturing operations and the regulatory status of their primary biosimilar candidate, AVT05. Impact of FDA's Complete Response Letter The investigation stems...

Continue Reading